Healthcare Biosimilar drug Pegfilgrastim a large opportunity, says Biocon Updated : June 05, 2018 11:26 PM IST Fulphila is the first FDA-approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon's joint portfolio approved in the US. Biocon is expected to launch the drug in FY19. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.